Publikationen

Publikationen im Thema Vaskulitis von Mitgliedern der VASAS - 2023

  1. Frank Moosig, Paolo Bottero, Alberto Pesci, et al: Cluster Analysis to Explore Clinical Subphenotypes of Eosinophilic Granulomatosis With Polyangiitis. The Journal of Rheumatology 2023;50:1446–53. doi:10.3899/jrheum.2023-0325

  2. Geetha D, Dua A, Yue H, et al. ADVOCATE Study Group. Efficacy and safety of avacopan in patients with ANCA-associated vasculitis receiving rituximab in a randomised trial. Ann Rheum Dis. 2023 Nov 18:ard-2023-224816. doi: 10.1136/ard-2023-224816. PMID: 37979959

  3. Hemmig AK, Aschwanden M, Berger CT, et al. Prior polymyalgia rheumatica is associated with sonographic vasculitic changes in newly diagnosed patients with giant cell arteritis. Rheumatology (Oxford). 2023 Aug 30: doi: 10.1093/rheumatology/kead450. Online ahead of print. PMID: 37647653

  4. Mensch N, Hemmig AK, Aschwanden M, et al. Rapid glucocorticoid tapering regimen in patients with giant cell arteritis: a single centre cohort study. RMD Open. 2023 Jul;9(3):e003301. doi: 10.1136/rmdopen-2023-003301. PMID: 37460275

  5. Hemmig AK, Aschwanden M, Seiler S, et al. Long delay from symptom onset to first consultation contributes to permanent vision loss in patients with giant cell arteritis: a cohort study. RMD Open. 2023 Jan;9(1):e002866. doi: 10.1136/rmdopen-2022-002866. PMID: 36635003

  6. Hemmig AK, Aschwanden M, Imfeld S, et al. A diagnostic performance study of the 2022 American College of Rheumatology/EULAR classification criteria for giant cell arteritis in a cohort of patients presenting with suspected giant cell arteritis. Arthritis Rheumatol. 2023 Jun;75(6):1075-1077. doi: 10.1002/art.42440. PMID: 36622332

  7. Rose K, Turner JE, Iking-Konert C. [Immunoglobulin A vasculitis (IgAV)]. Z Rheumatol. 2023 Sep;82(7):587-598. doi: 10.1007/s00393-023-01355-0.

  8. Cortazar FB, Niles JL, Jayne DRW, et al. ADVOCATE Study Group. Renal Recovery for Patients with ANCA-Associated Vasculitis and Low eGFR in the ADVOCATE Trial of Avacopan. Kidney Int Rep. 2023 Feb 3;8(4):860-870. doi: 10.1016/j.ekir.2023.01.039. PMID: 37069984

  9. Giacomo Emmi, Alessandra Bettiol, et al. Evidence-Based Guideline for the diagnosis and management of eosinophilic granulomatosis with polyangiitis. Nat Rev Rheumatol. 2023 Jun;19(6):378-393. doi: 10.1038/s41584-023-00958-w.

  10. Wolfgang A Schmidt, Bhaskar Dasgupta, Jennifer Sloane, et al. A phase 3 randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of sarilumab in patients with giant cell arteritis. Arthritis Res Ther. 2023 Oct 16;25(1):199. doi: 10.1186/s13075-023-03177-6.

  11. Robert F Spiera, Sebastian Unizony, Kenneth J Warrington, et al (SAPHYR Investigators) Sarilumab for Relapse of Polymyalgia Rheumatica during Glucocorticoid Taper. N Engl J Med. 2023 Oct 5;389(14):1263-1272. doi: 10.1056/NEJMoa2303452.

  12. Lisa Christ, Andrea D Gloor, Florian Kollert, et al. Serum proteomics in giant cell arteritis in response to a three-day pulse of glucocorticoid followed by tocilizumab monotherapy (the GUSTO trial) Front Immunol. 2023 May 23:14:1165758. doi: 10.3389/fimmu.2023.1165758. eCollection 2023.

  13. Michele Iudici, Andrea Katharina Hemmig, Mihaela Stegert, et al. Giant Cell Arteritis SCQM Study Group. Management of giant-cell arteritis in Switzerland: an online national survey Swiss Med Wkly. 2023 Apr 3:153:40051. doi: 10.57187/smw.2023.40051.

Ärzte Login

Patienten Login